DrugCite
Search

SANDOSTATIN LAR

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Sandostatin Lar Adverse Events Reported to the FDA Over Time

How are Sandostatin Lar adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Sandostatin Lar, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Sandostatin Lar is flagged as the suspect drug causing the adverse event.

Most Common Sandostatin Lar Adverse Events Reported to the FDA

What are the most common Sandostatin Lar adverse events reported to the FDA?

Diarrhoea
3335 (3.41%)
Fatigue
2339 (2.39%)
Nausea
1931 (1.97%)
Blood Pressure Increased
1841 (1.88%)
Abdominal Pain
1679 (1.72%)
Asthenia
1654 (1.69%)
Pain
1376 (1.41%)
Malaise
1370 (1.4%)
Blood Pressure Systolic Increased
1335 (1.36%)
Vomiting
1303 (1.33%)
Weight Decreased
1250 (1.28%)
Show More Show More
Headache
1219 (1.25%)
Dyspnoea
1204 (1.23%)
Injection Site Pain
1174 (1.2%)
Death
1172 (1.2%)
Oedema Peripheral
1094 (1.12%)
Dizziness
1074 (1.1%)
Abdominal Distension
933 (.95%)
Flushing
920 (.94%)
Fall
905 (.93%)
Pain In Extremity
875 (.89%)
Arthralgia
759 (.78%)
Abdominal Pain Upper
755 (.77%)
Back Pain
722 (.74%)
Neoplasm Malignant
717 (.73%)
Decreased Appetite
701 (.72%)
Flatulence
639 (.65%)
Cough
607 (.62%)
Nasopharyngitis
586 (.6%)
Abdominal Discomfort
570 (.58%)
Heart Rate Increased
552 (.56%)
Pyrexia
537 (.55%)
Blood Glucose Increased
506 (.52%)
Gait Disturbance
502 (.51%)
Constipation
477 (.49%)
Blood Pressure Decreased
476 (.49%)
Anxiety
460 (.47%)
Heart Rate Decreased
454 (.46%)
Chest Pain
440 (.45%)
Musculoskeletal Pain
431 (.44%)
Pneumonia
424 (.43%)
Heart Rate Irregular
419 (.43%)
Contusion
404 (.41%)
Alopecia
400 (.41%)
Hyperhidrosis
398 (.41%)
Loss Of Consciousness
397 (.41%)
Haemoglobin Decreased
393 (.4%)
Hypoaesthesia
366 (.37%)
Dehydration
365 (.37%)
General Physical Health Deteriorati...
355 (.36%)
Stress
351 (.36%)
Chills
349 (.36%)
Injection Site Mass
348 (.36%)
Hypotension
342 (.35%)
Palpitations
340 (.35%)
Drug Ineffective
336 (.34%)
Malignant Neoplasm Progression
336 (.34%)
Injection Site Haemorrhage
332 (.34%)
Urinary Tract Infection
331 (.34%)
Neoplasm Progression
330 (.34%)
Muscle Spasms
327 (.33%)
Pruritus
323 (.33%)
Hypertension
318 (.33%)
Feeling Abnormal
317 (.32%)
Insomnia
316 (.32%)
Balance Disorder
285 (.29%)
Influenza
281 (.29%)
Gastrointestinal Disorder
280 (.29%)
Intestinal Obstruction
273 (.28%)
Confusional State
270 (.28%)
Hot Flush
269 (.27%)
Anaemia
265 (.27%)
Weight Increased
264 (.27%)
Rash
261 (.27%)
Hypophagia
259 (.26%)
Depression
257 (.26%)
Syncope
253 (.26%)
Influenza Like Illness
250 (.26%)
Erythema
240 (.25%)
Paraesthesia
233 (.24%)
Pallor
230 (.24%)
Blood Pressure Diastolic Decreased
228 (.23%)
Joint Swelling
227 (.23%)
Myalgia
227 (.23%)
Somnolence
219 (.22%)
Gastrooesophageal Reflux Disease
218 (.22%)
Rectal Haemorrhage
217 (.22%)
Infection
215 (.22%)
Oropharyngeal Pain
215 (.22%)
Nephrolithiasis
213 (.22%)
Nervousness
213 (.22%)
Nasal Congestion
211 (.22%)
Sepsis
203 (.21%)
Cerebrovascular Accident
202 (.21%)
Metastases To Liver
191 (.2%)
Dyspepsia
190 (.19%)
Injection Site Haematoma
188 (.19%)
Tremor
186 (.19%)
Feeling Cold
185 (.19%)
Cholelithiasis
183 (.19%)
Vertigo
181 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Sandostatin Lar, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Sandostatin Lar is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Sandostatin Lar

What are the most common Sandostatin Lar adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Sandostatin Lar, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Sandostatin Lar is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Sandostatin Lar According to Those Reporting Adverse Events

Why are people taking Sandostatin Lar, according to those reporting adverse events to the FDA?

Acromegaly
1629
Carcinoid Tumour
1612
Neuroendocrine Tumour
1136
Carcinoid Syndrome
668
Metastatic Carcinoid Tumour
426
Pancreatic Neuroendocrine Tumour
340
Show More Show More
Neuroendocrine Carcinoma
267
Diarrhoea
139
Pancreatic Carcinoma
116
Hepatic Neoplasm Malignant
87
Small Intestine Carcinoma
72
Pancreatitis Chronic
68
Gastrinoma
65
Angiodysplasia
58
Pituitary Tumour
58
Pancreatic Neuroendocrine Tumour Me...
57
Short-bowel Syndrome
57
Vipoma
51
Metastatic Neoplasm
37
Pituitary Tumour Benign
35
Carcinoid Tumour Of The Gastrointes...
35
Metastases To Liver
35
Crohns Disease
35
Thyroid Cancer
34
Post Gastric Surgery Syndrome
33
Carcinoid Tumour Of The Small Bowel
31
Albrights Disease
31
Neoplasm Malignant
31
Carcinoid Tumour Pulmonary
30
Diabetic Retinopathy
29
Colon Cancer
25
Glucagonoma
25
Gastric Mucosal Hypertrophy
24
Intestinal Obstruction
23
Pancreatic Fistula
23
Drug Use For Unknown Indication
23
Neuroendocrine Carcinoma Metastatic
23
Product Used For Unknown Indication
23
Chylothorax
22
Hepatic Neoplasm
22
Insulinoma
21
Anaemia
20
Ovarian Neoplasm
20
Gastrointestinal Angiodysplasia
17
Gastrointestinal Cancer Metastatic
17
Ovarian Cancer
17
Pancreatitis
16
Hepatic Cancer Metastatic
15
Carcinoid Tumour Of The Pancreas
15
Lung Neoplasm Malignant
15
Thymoma
14

Drug Labels

LabelLabelerEffective
Sandostatin Lar DepotNovartis Pharmaceuticals Corporation31-DEC-11
Sandostatin Lar Depot Demonstration KitNovartis Pharmaceuticals Corporation31-DEC-11

Sandostatin Lar Case Reports

What Sandostatin Lar safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Sandostatin Lar. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Sandostatin Lar.